BioCryst Pharma (BCRX) Reports Q4 Loss of $0.40/sh
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.80 -7.46%
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.40), versus ($0.34) reported last year. Revenue for the quarter came in at $47.2 million, versus $4 million reported last year.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Globant (GLOB) Misses Q2 EPS by 10c, Offers Guidance
- TMC the metals company Inc. (TMC) Misses Q2 EPS by 8c
- Amaya (AYA) Misses Q2 EPS by 16c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
